Literature DB >> 1108210

Bone and marrow imaging in sickle cell disease: diagnosis of infarction.

L G Lutzker, A Alavi.   

Abstract

Sickling of erythrocytes in patients with S-hemoglobin causes marrow and bone infarction. The former can be demonstrated as a lack of 99mTc-sulfur colloid uptake on marrow imaging examination. These defects may resolve or persist long after the acute episode. If the bone is involved in the acute episode, imaging within the first few days of onset of symptoms can show lack of 99mTc-labeled phosphate uptake, usually in a smaller area than that shown by marrow scanning. Follow-up bone imaging shows increased activity, particularly along the circumference of the bone where periosteal reaction can be demonstrated radiographically. Magnification by use of the pinhole collimator provides better definition of the uptake defect and the distribution of the increased reactive uptake. Timing of examination is important. If marrow imaging is performed in an asymptomatic period, the repeat examination during a painful crisis permits differentiation of old and acute marrow infarction. If 99mTc-phosphate imaging is performed after about 2 days of symptoms, acute infarction can be differentiated from osteomyelitis, which it may mimic clinically. Although osteomyelitis may cause no increased activity in the first 48 hr after onset of symptoms, it is characterized by intense focal activity thereafter (see article by Handmaker in this issue). To assist in differentiating bone infection in a site of marrow infarction demonstrated by marrow imaging, serial bone imaging with magnification may be useful. The uptake defect, followed in several days to 2 weeks, by circumferential increased activity, is a different pattern than the homogeneously intense activity of osteomyelitis, but the peripheral distribution may not be apparent on routine imaging. It is hoped that the utilization of these techniques can decrease the emotional and economic costs of prolonged hospitalization for suspected infection and can also expand our knowledge of the complex pathophysiologic changes of sickle cell bone disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1108210     DOI: 10.1016/s0001-2998(76)80038-4

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  9 in total

1.  Case report 430: Ischemic necrosis of osteochondroma of tibia.

Authors:  E C Unger; L A Gilula; M Kyriakos
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

2.  Bone infarction in children with sickle cell disease: early diagnosis and differentiation from osteomyelitis.

Authors:  A Koren; I Garty; E Katzuni
Journal:  Eur J Pediatr       Date:  1984-06       Impact factor: 3.183

3.  Uncommon sites of bone infarction in a sickle cell anemia patient.

Authors:  I Garty; A Koren; E Katzumi
Journal:  Eur J Nucl Med       Date:  1983

4.  Scintigraphic photopenia in sacrococcygeal chordoma.

Authors:  W J Shih; R C Reba; T Y Huang
Journal:  Eur J Nucl Med       Date:  1983

5.  Stress fractures of the femoral neck: a scintigraphic sign for early diagnosis.

Authors:  G Y El-Khoury; M A Wehbe; M Bonfiglio; K C Chow
Journal:  Skeletal Radiol       Date:  1981       Impact factor: 2.199

6.  An unusual scintigraphic pattern in sickle cell patients.

Authors:  A M Glaser; D C Chen; M E Siegel; S L Norris; L J Haywood
Journal:  Eur J Nucl Med       Date:  1989

7.  [Scintigraphic findings in a patient with sickle-cell thalassemia and recurrent pain attacks].

Authors:  Peter Mikosch; Barbara Jauk; Wilhelm Kaulfersch; Hans-Jürgen Gallowitsch; Peter Lind
Journal:  Wien Med Wochenschr       Date:  2003

8.  Femoral neck fractures complicating Gaucher disease in children.

Authors:  A B Goldman; B Jacobs
Journal:  Skeletal Radiol       Date:  1984       Impact factor: 2.199

Review 9.  Radionuclide imaging of bone marrow disorders.

Authors:  Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.